BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10400413)

  • 1. Selection of BCR/ABL-negative stem cells from marrow or blood of patients with chronic myeloid leukemia.
    Guyotat D; Wahbi K; Viallet A; Piselli S; Campos L
    Leukemia; 1999 Jul; 13(7):991-8. PubMed ID: 10400413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
    Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
    Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Fluorouracil-resistant CD34+ cell population from peripheral blood of CML patients contains BCR-ABL-negative progenitor cells.
    Jazwiec B; Mahon FX; Pigneux A; Pigeonnier V; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1509-14. PubMed ID: 8542939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow.
    Leemhuis T; Leibowitz D; Cox G; Silver R; Srour EF; Tricot G; Hoffman R
    Blood; 1993 Feb; 81(3):801-7. PubMed ID: 7679000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
    Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
    Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
    Maguer-Satta V; Petzer AL; Eaves AC; Eaves CJ
    Blood; 1996 Sep; 88(5):1796-804. PubMed ID: 8781437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does long-term culture favor normal clonogenic cells from interferon-treated patients with chronic myelogenous leukemia?
    Pasternak G; Schultheis B; Heissig B; Hörner S; Sick C; Hehlmann R
    Leukemia; 1999 Apr; 13 Suppl 1():S55-64. PubMed ID: 10232367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients.
    Grand FH; Marley SB; Chase A; Titley I; Healy L; Spencer A; Reiter A; Goldman JM; Gordon MY
    Leukemia; 1997 Sep; 11(9):1486-92. PubMed ID: 9305602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of hematopoietic colonies derived from chronic myeloid leukemia patients: interphase fluorescence in situ hybridization compared with RT-PCR.
    Thijsen SF; Schuurhuis GJ; van Oostveen JW; Theijsmeijer AP; Langenhuijsen MM; Ossenkoppele GJ
    Leukemia; 1997 Feb; 11(2):301-5. PubMed ID: 9009097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells.
    Savoldo B; Sammarelli G; Dotti G; Garau D; Regazzi E; Cilloni D; Tabilio A; Rizzoli V; Carlo-Stella C
    Leukemia; 1998 Mar; 12(3):434-40. PubMed ID: 9529140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
    Lin H; Monaco G; Sun T; Ling X; Stephens C; Xie S; Belmont J; Arlinghaus R
    Oncogene; 2005 May; 24(20):3246-56. PubMed ID: 15735695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E; Krahl R; Thalmeier K; Helbig W
    Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.
    Schultheis B; Heissig B; Pasternak G; Hörner S; Hehlmann R
    Folia Biol (Praha); 2000; 46(6):251-5. PubMed ID: 11140858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration.
    Petzer AL; Hochenburger E; Haun M; Duba HCh; Grünewald K; Hoflehner E; Sill H; Linkesch W; Gastl G; Gunsilius E
    J Hematother Stem Cell Res; 2002 Apr; 11(2):293-300. PubMed ID: 11983100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
    Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
    Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.
    Holyoake T; Jiang X; Eaves C; Eaves A
    Blood; 1999 Sep; 94(6):2056-64. PubMed ID: 10477735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice.
    Verstegen MM; Cornelissen JJ; Terpstra W; Wagemaker G; Wognum AW
    Leukemia; 1999 Apr; 13(4):618-28. PubMed ID: 10214871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal.
    Delforge M; Boogaerts MA; McGlave PB; Verfaillie CM
    Blood; 1999 Jan; 93(1):284-92. PubMed ID: 9864172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors.
    Kasper B; Fruehauf S; Schiedlmeier B; Buchdunger E; Ho AD; Zeller WJ
    Cancer Chemother Pharmacol; 1999; 44(5):433-8. PubMed ID: 10501919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.